BioAtla Inc (BCAB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.52-4.40%
Close 2026-09-24 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · BCAB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
BCAB — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-10-19
Unregistered Sales of Equity Securities. The information contained in
Why it matters: A completed sale could bring cash to BioAtla. No deal would leave its strategic plan unclear.
Supportive ifBioAtla files an 8-K or press release naming an asset sale or other strategic deal and its terms.
Worry ifBioAtla reports that talks ended, or makes no deal announcement in the next reported update.
Why it matters: A confirmed staff cut would show that the restructuring is moving ahead. The filings may also show its cost and cash impact.
Watch forA company filing states the number of roles cut and the expected cost savings or charges.
Also watch forThe company says it canceled the workforce plan or reports no staff cuts in its next update.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$356 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $1,740 loss on $10,000 · 17.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,802 loss on $10,000 · 98.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.